Merck (NYSE: MRK) reported its third quarter 2024 earnings results today. Sales grew 4% year-over-year to $16.7 billion. Excluding FX, sales growth was 7%. GAAP net income decreased 33% to $3.15 billion, or $1.24 per share, compared to last year. Adjusted EPS fell 26% to $1.57. For the full year of 2024, the company expects […]
Merck (NYSE: MRK) reported its third quarter 2024 earnings results today. Sales grew 4% year-over-year to $16.7 billion. Excluding FX, sales growth was 7%. GAAP net income decreased 33% to $3.15 billion, or $1.24 per share, compared to last year. Adjusted EPS fell 26% to $1.57. For the full year of 2024, the company expects […]
Merck (NYSE: MRK) reported its third quarter 2024 earnings results today.
Sales grew 4% year-over-year to $16.7 billion. Excluding FX, sales growth was 7%.
GAAP net income decreased 33% to $3.15 billion, or $1.24 per share, compared to last year. Adjusted EPS fell 26% to $1.57.
For the full year of 2024, the company expects sales of $63.6-64.1 billion and adjusted EPS of $7.72-7.77.
